Evaluating the costs of adverse drug events in hospitalized patients: a systematic review

Maxime Durand (), Christel Castelli, Clarisse Roux-Marson, Jean-Marie Kinowski and Géraldine Leguelinel-Blache
Additional contact information
Maxime Durand: Nîmes University Hospital, Univ Montpellier
Christel Castelli: Univ Montpellier
Clarisse Roux-Marson: Nîmes University Hospital, Univ Montpellier
Jean-Marie Kinowski: Nîmes University Hospital, Univ Montpellier
Géraldine Leguelinel-Blache: Nîmes University Hospital, Univ Montpellier

Health Economics Review, 2024, vol. 14, issue 1, 1-14

Abstract: Abstract Background Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate the methods to calculate these costs, and to characterize their nature. Methods A systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients. Results From 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values. Conclusions There is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation. Trial registration PROSPERO registration CRD42023413071.

Keywords: Systematic review; Adverse drug events; Costs; Health economics; Pharmacovigilance (search for similar items in EconPapers)
Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-024-00481-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00481-y

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-024-00481-y

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().